Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

Brentuximab vedotin (BV) significantly improved progression-free survival in a phase 3 study in patients with relapsed or refractory Hodgkin lymphoma (RR-HL) post-autologous-haematopoietic stem cell transplant (HSCT); we report the impact of BV on quality of life (QOL) from this trial. The European...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Haematol
Auteurs principaux: Ramsey, Scott D., Nademanee, Auayporn, Masszi, Tamas, Holowiecki, Jerzy, Abidi, Muneer, Chen, Andy, Stiff, Patrick, Viviani, Simonetta, Sweetenham, John W., Radford, John, Zhu, Yanyan, Bonthapally, Vijayveer, Thomas, Elizabeth, Richhariya, Akshara, Hunder, Naomi N., Walewski, Jan, Moskowitz, Craig H.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5621593/
https://ncbi.nlm.nih.gov/pubmed/27649689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14316
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires